Evidence map›Paper›PMID 30761448›Full record

ArticleIndian journal of pediatrics2019

Intestinal Failure-Associated Liver Disease and Eicosapentaenoic Acid/Arachidonic Acid Ratio.

Wataru Miura, Nobuhiko Nagano, Ryota Kato, Aya Okahashi, Kayo Yoshikawa, Kensuke Ohashi, Tsugumichi Koshinaga, Ichiro Morioka

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Indian journal of pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wataru MiuraDepartment of Pediatrics and Child Health, Nihon University School of Medicine, 30-1 Oyaguchi, Kami-Cho, Itabashi-ku, Tokyo, 173-8610, Japan.
Nobuhiko NaganoDepartment of Pediatrics and Child Health, Nihon University School of Medicine, 30-1 Oyaguchi, Kami-Cho, Itabashi-ku, Tokyo, 173-8610, Japan. nagano.nobuhiko@nihon-u.ac.jp.ORCID 0000-0002-0890-1626
Ryota KatoDepartment of Pediatrics and Child Health, Nihon University School of Medicine, 30-1 Oyaguchi, Kami-Cho, Itabashi-ku, Tokyo, 173-8610, Japan.
Aya OkahashiDepartment of Pediatrics and Child Health, Nihon University School of Medicine, 30-1 Oyaguchi, Kami-Cho, Itabashi-ku, Tokyo, 173-8610, Japan.
Kayo YoshikawaDepartment of Pediatrics and Child Health, Nihon University School of Medicine, 30-1 Oyaguchi, Kami-Cho, Itabashi-ku, Tokyo, 173-8610, Japan.
Kensuke OhashiDepartment of Pediatric Surgery, Nihon University School of Medicine, Tokyo, Japan.
Tsugumichi KoshinagaDepartment of Pediatric Surgery, Nihon University School of Medicine, Tokyo, Japan.
Ichiro MoriokaDepartment of Pediatrics and Child Health, Nihon University School of Medicine, 30-1 Oyaguchi, Kami-Cho, Itabashi-ku, Tokyo, 173-8610, Japan.
Nihon University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intestinal failure-associated liver disease (IFALD) is a fatal complication of short bowel syndrome managed with parenteral nutrition. A clinical cohort study reported the usefulness of parenteral administration of fish-derived omega-3 fatty acids in improving IFALD; however, no biomarker has been developed as yet. The authors report the case of a preterm infant with IFALD complicated by extensive short bowel syndrome. Intravenous administration of omega-3 fatty acids were introduced using Omegaven®at the age of 4 mo for IFALD. The IFALD improved with an increase in Eicosapentaenoic acid (EPA)/ Arachidonic acid (AA) ratio (from 0.08 to 1.99) 7 d after the intravenous treatment. It is important to administer omega-3 fatty acids intravenously at an early stage for IFALD associated with extensive short bowel syndrome. A low EPA/AA ratio may be a serum marker of disease activity in IFALD.

Indexed as

Administration, OralArachidonic AcidBiomarkersEicosapentaenoic AcidFatty Acids, Omega-3FemaleHumansInfant, NewbornInfusions, IntravenousIntestinal DiseasesLiver DiseasesShort Bowel SyndromeArachidonic AcidBiomarkersEicosapentaenoic AcidFatty Acids, Omega-3Eicosapentaenoic acid/Arachidonic acid ratioIntestinal failure-associated liver diseaseIntravenous administrationOmega-3 fatty acidsSevere short bowel syndrome

Identifiers

PMID30761448
OpenAlexW2914797834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.